Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. 2000

M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.

OBJECTIVE To compare acute and late toxicities of high-dose radiation for prostate cancer delivered by either conventional three-dimensional conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT). METHODS Between September 1992 and February 1998, 61 patients with clinical stage T1c- T3 prostate cancer were treated with 3D-CRT and 171 with IMRT to a prescribed dose of 81 Gy. To quantitatively evaluate the differences between conventional 3D-CRT and IMRT, 20 randomly selected patients were planned concomitantly by both techniques and the resulting treatment plans were compared. Acute and late radiation-induced morbidity was evaluated in all patients and graded according to the Radiation Therapy Oncology Group toxicity scale. RESULTS Compared with conventional 3D-CRT, IMRT improved the coverage of the clinical target volume (CTV) by the prescription dose and reduced the volumes of the rectal and bladder walls carried to high dose levels (P<0.01), indicating improved conformality with IMRT. Acute and late urinary toxicities were not significantly different for the two methods. However, the combined rates of acute grade 1 and 2 rectal toxicities and the risk of late grade 2 rectal bleeding were significantly lower in the IMRT patients. The 2-year actuarial risk of grade 2 bleeding was 2% for IMRT and 10% for conventional 3D-CRT (P<0.001). CONCLUSIONS The data demonstrate the feasibility and safety of high-dose IMRT for patients with localized prostate cancer and provide a proof-of-principle that this method improves dose conformality relative to tumor coverage and exposure to normal tissues.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011880 Radiotherapy Planning, Computer-Assisted Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy. Computer-Assisted Radiotherapy Planning,Dosimetry Calculations, Computer-Assisted,Planning, Computer-Assisted Radiotherapy,Calculation, Computer-Assisted Dosimetry,Calculations, Computer-Assisted Dosimetry,Computer Assisted Radiotherapy Planning,Computer-Assisted Dosimetry Calculation,Computer-Assisted Dosimetry Calculations,Dosimetry Calculation, Computer-Assisted,Dosimetry Calculations, Computer Assisted,Planning, Computer Assisted Radiotherapy,Radiotherapy Planning, Computer Assisted
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D012449 Safety Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property. Safeties

Related Publications

M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
January 2015, Revista da Associacao Medica Brasileira (1992),
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
January 2002, Medical dosimetry : official journal of the American Association of Medical Dosimetrists,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
January 2004, Cancer investigation,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
June 2011, Nihon rinsho. Japanese journal of clinical medicine,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
June 2010, Nihon rinsho. Japanese journal of clinical medicine,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
April 2006, Gan to kagaku ryoho. Cancer & chemotherapy,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
May 2016, Nihon rinsho. Japanese journal of clinical medicine,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
September 2005, Nihon rinsho. Japanese journal of clinical medicine,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
September 2015, Physics in medicine and biology,
M J Zelefsky, and Z Fuks, and L Happersett, and H J Lee, and C C Ling, and C M Burman, and M Hunt, and T Wolfe, and E S Venkatraman, and A Jackson, and M Skwarchuk, and S A Leibel
March 2003, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!